Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AVIR, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Bemnifosbuvir-Ruzasvir | HEPATITIS C VIRUS CHRONIC INFECTION | Phase 3 · NCT06868264 | Completed |
| Bemnifosbuvir | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection) | Phase 3 · NCT05629962 | Completed |
| Sofosbuvir-Velpatasvir | HEPATITIS C VIRUS CHRONIC INFECTION | Phase 3 · NCT06868264 | Completed |
| Bemnifosbuvir Sulfate (AT-527) | COVID-19 | Phase 3 · NCT04889040 | Terminated |
| AT-777 | Hepatitis C | Phase 1/2 · NCT04309734 | Withdrawn |
| Daclatasvir | Hepatitis C | Phase 2 · NCT04019717 | Completed |
| AT-752 | Dengue Fever | Phase 2 · NCT05466240 | Terminated |
| Ruzasvir | Chronic Hepatitis C Virus | Phase 2 · NCT05904470 | Completed |
| Moxifloxacin | Healthy Volunteer Study | Phase 1 · NCT05905484 | Completed |
| Rosuvastatin | Healthy Volunteer Study | Phase 1 · NCT05154123 | Completed |
| Ethinyl Estradioll/Levonorgestrel (EE/LNG) | Healthy Volunteer Study | Phase 1 · NCT07272889 | Completed |
| Methadone | Healthy Volunteer Study | Phase 1 · NCT07314346 | Completed |
| Period 1: AT-527 550 mg | Healthy Volunteer Study | Phase 1 · NCT04784000 | Completed |
| Period 2: carbamazepine | Healthy Volunteer Study | Phase 1 · NCT04784000 | Completed |
| Treatment A-Bemnifosbuvir/Ruzasvir FDC… | Healthy Volunteer Study | Phase 1 · NCT07007806 | Completed |
| Naloxone | Healthy Volunteer Study | Phase 1 · NCT07314346 | Completed |
Also used in these trials (approved or third-party drugs, not AVIR's own candidates): Omeprazole, Carbamazepine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
AVIR holds $191.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $33M/quarter from operations, an estimated runway of 17.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 38 · Moderate
We believe that our available cash, including the $65.0 million that we have drawn under the Loan and Security Agreement, cash equivalents and marketable securities will be sufficient to fund our planned operations into mid-2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AVIR files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR LLC | Institution (13G, 5%+) | 11,950,772 | 14.88% | 2026-03-31 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director · +440,000 options |
Insider | 9,080,450 | 11.31% | 2026-09-30 |
| Leonard Braden Michael | 5%+ holder (13G) | 7,810,000 | 9.73% | 2025-12-31 |
| TANG CAPITAL MANAGEMENT, LLC | 5%+ holder (13G) | 4,814,700 | 6.00% | 2026-10-06 |
| Andrea Corcoran Chief Financial Officer, Executive Vice · +380,000 options |
Insider | 823,576 | 1.03% | 2026-03-11 |
| Franklin M Berger Director · +146,800 options |
Insider | 536,097 | 0.67% | 2026-06-18 |
| John Vavricka Chief Commercial Officer · +252,320 options |
Insider | 165,102 | 0.21% | 2026-01-31 |
| Bruno Lucidi Director · +105,600 options |
Insider | 142,350 | 0.18% | 2026-06-18 |
| Janet MJ Hammond Chief Development Officer · +377,000 options |
Insider | 127,665 | 0.16% | 2026-01-31 |
| Bruce Polsky Director · +105,600 options |
Insider | 124,806 | 0.16% | 2026-06-18 |
| Polly A. Murphy Director · +105,600 options |
Insider | 121,745 | 0.15% | 2026-06-18 |
| Maria Arantxa Horga Chief Medical Officer · +366,300 options |
Insider | 96,086 | 0.12% | 2026-01-31 |
Share count 80,304,145 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AVIR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →